Somatostatin and its analogs
PreclinicalSmall molecule
Somatostatin and its analogs is one of 19 small molecule programs targeting Portal vein thrombosis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
23 competitors in Portal Vein Thrombosis
#DrugCompanyPhaseTrials
1Eliquis
Bristol-Myers SquibbApproved
Bayer Aspirin
BayerApproved
Coumadin
AAbbott
Approved
Persantine
Boehringer IngelheimApproved
Xarelto
WWim Janssens
Approved
Low-Molecular-Weight Heparin
Daiichi SankyoApproved
Lovenox
SanofiPhase 3
Pradaxa
Boehringer IngelheimPhase 3
Heparin Sodium
BBaxter Healthcare Corporation
Phase 3
Inderal
WWyeth-Lederle Vaccines
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details